News
4don MSN
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...
INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Pharmaceutical Technology on MSN18h
Eli Lilly and Eisai’s Alzheimer’s drugs denied NHS use due to high costsNICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...
Eli Lilly said on Thursday it would appeal against a UK agency's recommendation to not reimburse the cost of Alzheimer's drug ...
Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...
According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback